Myricetin Inhibits Islet Amyloid Polypeptide (IAPP) Aggregation and Rescues Living Mammalian Cells from IAPP Toxicity

Casey Zelusa, Ayano Foxa, Anastasia Calcianoa, Bianca S Faridianb, Luiza A Nogajb, David A Moffeta, *
a Department of Chemistry and Biochemistry, Loyola Marymount University, 1 LMU Drive Los Angeles, CA 90045, USA
b Department of Biology, Mount Saint Mary’s College 12001 Chalon Rd, Los Angeles, CA 90049, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 312
Abstract HTML Views: 222
PDF Downloads: 72
Total Views/Downloads: 606
Unique Statistics:

Full-Text HTML Views: 133
Abstract HTML Views: 91
PDF Downloads: 47
Total Views/Downloads: 271

© Zelus et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: // which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Chemistry and Biochemistry, Loyola Marymount University, 1 LMU Drive Los Angeles, CA 90045, USA; Tel: 310-338-4400; Fax: 310-338-2905;E-mail:


The aggregation of the amyloidogenic polypeptide IAPP (Islet Amyloid Polypeptide, amylin) is believed to play a direct role in the death of pancreatic β-islet cells in type II diabetes. Preventing the initial aggregation event of IAPP is one strategy for slowing, and possibly preventing, the progression of this disease. Here, we investigate myricetin’s potential as an inhibitor of IAPP aggregation. We show that myricetin prevented thioflavin T binding in a concentration dependent manner. Atomic force microscopy revealed that myricetin prevented fiber formation under rigorous conditions conducive to forming IAPP aggregates. Using an IAPP-EGFP (Enhanced Green Fluorescent Protein) protein construct, we find that high concentrations of myricetin slowed the in vivo aggregation of IAPP-EGFP. Myricetin was also found to rescue living mammalian cells from the toxic effects of IAPP. These results indicate that myricetin is a strong inhibitor of IAPP amyloid aggregation and a potential lead molecule for the development of an amyloid inhibiting therapeutic.

Keywords: Type 2 diebetes, amyloid, amylin.